

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Michael Conor MINOGUE

Michael Louis CROWE

U.S. Appln. No.

09/902,287

U.S. Filing Date

July 10, 2001

Title of Invention

AN ELECTROTHERAPY DEVICE AND

METHOD

745 effth Avernor New York, New York 1015

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Asst. Commissioner Patents and Trademarks Washington, DC 20231, on April 2, 2002

Gordon M. Kessler Reg. No. 38,511

Name of Applicant, Assignee or Register Representative

Signature

4/9/02.

Date of Signature

PETITION TO MAKE SPECIAL – INFRINGEMENT INFORMATION DISCLOSURE STATEMENT, AND REQUEST FOR INTERVIEW PRIOR TO FIRST OFFICE ACTION

Assistant Commissioner for Patents Box PATENT APPLICATION (35 U.S.C. 111) Washington, D.C. 20231 Sir:

INFORMATION DISCLOSURE STATEMENT

The Examiner's attention is respectfully directed to the documents cited in the accompanying PTO 1449 (submitted in duplicate). A copy of each of these documents is attached for the application file.

The Examiner is respectfully requested to consider and make of record the documents cited and return to the undersigned an initialed PTO 1449 showing that the documents have indeed been considered and made of record.

It is believed that no fee is due for entry of this Information Disclosure Statement as it is submitted prior to receipt of the first Office Action in this application. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee, or credit any overpayment, against Deposit Account No. 50-0320.

PETITION TO MAKE SPECIAL - INFRINGEMENT

Pursuant to 37 C.F.R. §1.102 and MPEP §708.01 and § 708.02 (II) and any other Rules of the Commissioner and MPEP sections, Applicants respectfully petition to make this application special on the basis of infringement occurring by third parties. A check for \$130.00 in payment of the fee set forth in 37 C.F.R. §1.17(h) is enclosed; and, the Commissioner is hereby authorized to charge any additionally required fee for this petition or for making the application special or credit any overpayment in such fees to Deposit Account No. 50-0320.

The undersigned is an attorney registered to practice before the PTO, as required by MPEP §708.02.

A careful and thorough search of the prior art was made and the documents uncovered by that search are submitted herewith, as shown by the foregoing Information Disclosure Statement, as required by MPEP §708.02.

The present application claims a device for attaching electrodes to a subject for stimulating abdominal muscles by electrotherapy. According to one aspect, the invention provides an attachment means that can be extended around the torso of a user. The attachment means, that may be in the form of a belt, is provided with electrode locating means for locating at least three electrodes designed so that a central electrode may be located relative to the umbilicus of the subject and two side electrodes are located to the either side of the central electrode. When electrical pulses are applied to the electrodes electrical currents stimulate the subject's abdominal muscle groups. See Claim 1. The present application also claims that side electrodes are positioned toward the left and right mid-axillary lines of the subject. See, e.g., Claims 2-5. This positioning has been found particularly advantageous for exercising the rectus abdominus, the traversalis, and the oblique muscle groups using a minimum number of electrodes. See

Specification, pages 14-16, and 27.

In addition, the application claims multiple locating means for positioning the side electrodes at different locations relative to the central electrode to accommodate subjects of

different girths. See Claim 12. The application also claims a method for stimulating abdominal muscles that comprises the steps of positioning three electrodes on the abdomen of a subject, one adjacent to the umbilicus and two located toward the mid-axillary lines and applying an electrical current between the electrodes. See Claim 52.

Applicants' assignee, Bio-Medical Research, Ltd. ("BMR"), has become aware of a competitor in the United States – The Dezac Group, Ltd. ("Dezac") – selling a electrical muscle stimulator device under the name RIO AB BELT, which is within the claims of the present invention. Dezac sells the RIO AB BELT in the United States through retailers that advertise on the world wide web. Attached as Exhibits A and B are pages from websites of retailers offering the AB BELT for sale in the United States.

Attached as Exhibit C is a copy of the instruction manual (the "Manual") provided along with the RIO AB BELT. As shown at page 3 of the Manual, the AB BELT includes a belt and control unit (1) and electrode pads (3). The electrode pads are connected to the inside surface of the belt by press studs, and can be positioned in two configurations, denoted "Position I – Inner Muscle Group" and "Position II – Outer Muscle Group." Manual at 4-6. The control unit is positioned on the outside of the belt, opposite the central electrode. Id. at 5. A photograph on the front cover of the Manual shows a model wearing the AB BELT with the control unit positioned at the center of her abdomen over her umbilicus. As discussed at page 5-of the manual, the control unit can be adjusted to deliver electrical pulses according to one of three selectable programs to stimulate the user's abdominal muscles.

A rigid comparison of the RIO AB BELT with the claims of the application reveals that at least some of the claims are unquestionably infringed. As compared with claims 1-5 and 52, the AB BELT provides an attachment means (i.e., a belt) with locating means (i.e., press studs) for attaching at least three electrodes, a central electrode and two side electrodes. See Manual at 4-6. When worn as instructed the central electrode is positioned adjacent to the user's umbilicus and the side electrodes are positioned toward the mid point of the mid-axillary lines of the user between the rib cage and the corresponding iliac crest. Id. at front cover and 6. Electrical pulses are applied to these electrodes to stimulate the user's abdominal muscles. Id. at 5. With respect to claim 12, there are two locating means for each side electrode, shown as Position I and Position II at page 6 of the Manual for accommodating users of different girths. Thus, at least some of the claims of the application are unquestionably infringed by the AB BELT.

3

00051217

Accordingly, it is respectfully submitted that all of the requirements of MPEP §708.02 (II) have been met, namely the petition fee is enclosed herewith and this paper is a petition to make special and:

- (1) That there is an infringing product actually on the market or methods in use;
- (2) That a comparison of the alleged infringing product, or methods with the claims of the application has been made, and that, in the opinion of the undersigned, some of the claims of the application are unquestionably infringed; and
- (3) That there has been a careful and thorough search of the prior art (with a copy of the references therefrom supplied herewith).

It is respectfully submitted that BMR is suffering by not having a U.S. Patent corresponding to the present application. Until a U.S. Patent corresponding to the present application issues, BMR is without any remedy to prevent infringement; and, without a U.S. Patent corresponding to the present application, BMR is faced with lost sales and revenue due to competitive products and methods within at least one claim of the present application.

Therefore, it is respectfully submitted that the present application qualifies for special status; and, according the present application special status is respectfully requested.

Fig. 1. States and the second second second. REQUEST FOR INTERVIEW

In addition, if there is any issue that presents an impediment to first action allowance of the present application, an interview is respectfully requested prior to any first Office Action on the merits.

Thus, Applicants respectfully request an interview prior to any first Office Action; and, the Examiner is respectfully requested to contact the undersigned prior to issuing any first Office Action to arrange a mutually convenient time and manner for such an interview.

Any additionally required fee or overpayment in any fee occasioned by this paper may be charged or credited to Deposit Account No. 50-0320.

CONCLUSION

Early and favorable examination on the merits, special status, and first action allowance or an interview prior to any first Office Action (so any issues may be rapidly resolved), are all earnestly solicited.

profit of the first of the profit of the pro

gila medale teleggila deligió del medició e antició de milimolecia de antició de la colonida de la colónica de a

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

By____

Gordon M. Køssler

Registration No. 38,511

(212) 588-0800

Fax (212) 588-0500

Based on Form PTO-1449 (3/90)

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

660057-2005

09/902,287

APPLICANT

Michael Conor MINOGUE, et al.

FILING DATE

GROUP

July 10, 2001

		Doorn com	DATE:	U.S. PATENT DOCUMENTS	61.466	cimci +cc	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	3,610,250	10/5/71	Sarbacher	128	379	
	AA	4,381,012	4/26/83	Russek	128	644	
	AB	4,432,368	2/21/84	Russek	128	644	
	AC.	4,583,547	4/22/86	Granek et al.	128	639	
	ĀD	4,729,377	3/8/88	Granek et al.	128	639	
	AE	5,443,494	8/22/95	Paolizzi et al.	607	149	
	AF	5,904,712	5/18/99	Axelgaard	607	148	
	AG	5,922,012	7/13/99	Sakano	607	46	
	AH	6,341,237	1/22/02	Hurtado	607	148	
	ΑI	194,520	8/28/1877	J. Hobbs			
	AJ	226,658	4/20/1880	T.W. Graydon			
	AK	276,078	4/17/1883	J. Rittig			
	AL	279,881	6/19/1883	G.E. Palmer			
	AM	372,647	11/1/1887	J. Williams			
	AN	880,041	2/25/08	H.B. Renton			
	AO	2,110,392	3/8/38	E.L. Dorr			
	AP	2,711,729	6/28/55	W. Hofmann			
	AQ	2,943,628	7/5/60	W.L. Howell			
	AR	3,409,007	11/5/68	E.W. Fuller			
	AS	3,534,727	10/20/70	James A. Roman			
	ΑT	3,881,495	5/6/75	Pannozzo et al.	128	422	
	AU	4,354,509	10/19/82	Strahwald et al.	128	803	
	AV	4,365,634	12/28/82	Bare et al.	128	640	
	AW	4,381,789	5/3/83	Naser at el.	128	798	
	AX	4,422,461	12/27/83	Glumac	128	798	
	AY	4,509,535	4/9/85	Bryan	128	798	
	AZ	4,556,214	12/3/85	Petrofsky et al.	272	117	
	AAA	4,633,888	1/6/87	Yoneyama	128	784	
	AAB	4,708,149	11/24/87	Axelgaard et al.	128	798	
	AAC	4,763,660	8/16/88	Kroll et al.	128	640	

(1900) PE OF OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) AAD 5,263,481 11/23/93 Axelgaard 128 640 AAE 5,336,255 8/9/94 Kanare et al. 607 149 AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 372 AAR 6,002,965 12/14/99 Katz et al. 607 149 AAL 6,002,965 12/14/99 Katz et al. 607 149 AAL 6,324,432 11/27/01 Rigaux et al. 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 149 AAU DES420,138 2/1/00 Robinette D24 200	PTO-1449				ATTY. DOCKET NO.		SERIAL NO. 09/902,287		
Michael Conor MINOGUE, FILING DATE July 10, 2001 July					660057-200				
July 10, 2001 U.S. PATENT DOCUMENTS AAD 5,263,481 11/23/93 Axelgaard 128 640 AAE 5,336,255 8/9/94 Kanare et al. 607 149 AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600	UST OF RE				APPLICANT				
July 10, 2001	or [8])						
AAD 5,263,481 11/23/93 Axelgaard 128 640 AAE 5,336,255 8/9/94 Kanare et al. 607 149 AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62					1	,,	GROO!		
AAD 5,263,481 11/23/93 Axelgaard 128 640 AAE 5,336,255 8/9/94 Kanare et al. 607 149 AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	Marie			*** ***	<u> </u>)1			
AAE 5,336,255 8/9/94 Kanare et al. 607 149 AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 149 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAU 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAD	5 262 401	11/22/02	T		120	640		
AAF 5,344,440 9/6/94 Stephen 607 139 AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	 		 	 			+		
AAG 5,397,337 3/14/95 Jaeger et al. 607 62 AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	 			+			-		
AAH 5,397,338 3/14/95 Grey et al. 607 115 AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	 		 	+					
AAI 5,487,759 1/30/96 Bastyr et al. 607 149 AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	 		 	 					
AAJ 5,601,618 2/11/97 James 607 71 AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	-						1		
AAK 5,622,168 4/22/97 Keusch et al. 128 640 AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62				 					
AAL 5,674,261 10/7/97 Smith 607 46 AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62						71		14.	
AAM 5,823,989 10/20/98 Ostrow 604 20 AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62		·	-	Keus	ch et al.	128	640		
AAN 5,871,534 2/16/99 Messick et al. 607 138 AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAL	5,674,261	10/7/97	Smit	h	607	46		
AAO 5,916,159 6/29/99 Kelly et al. 600 390 AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAM	5,823,989	10/20/98	Ostro	OW .	604	20		
AAP 5,947,897 9/7/99 Otake 600 372 AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAN	5,871,534	2/16/99	Mess	ick et al.	607	138		
AAQ 5,995,861 11/30/99 Price 600 37 AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAO	5,916,159	6/29/99	Kell	y et al.	600	390		
AAR 6,002,965 12/14/99 Katz et al. 607 48 AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAP	5,947,897	9/7/99	Otak	Э	600	372		
AAS 6,094,599 7/25/00 Bingham et al. 607 149 AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAQ	5,995,861	11/30/99	Price	e	600	37		
AAT 6,151,528 11/21/00 Maida 607 149 AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAR	6,002,965	12/14/99	Katz	et al.	607	48	-	
AAU 6,324,432 11/27/01 Rigaux et al. 607 62	AAS	6,094,599	7/25/00	Bingl	nam et al.	607	149		
	AAT	6,151,528	11/21/00	Maida	3	607	149		
AAV DES420,138 2/1/00 Robinette D24 200	AAU	6,324,432	11/27/01	Rigat	ıx et al.	607	62		
	AAV	DES420,138	2/1/00	Robin	nette	D24	200		
				1					
FOREIGN PATENT DOCUMENTS			FORE	IGN PA	TENT DOCUMENTS			····	,,,,=
DOCUMENT DATE COUNTRY CLASS SUBCLA			DATE	T	COUNTRY	CLASS	SUBCLASS	TRANS	LATIO
								YES	NO

EXAMINER

DATE CONSIDERED

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Initial if reference considered, whether or not citation is in conformance * EXAMINER: with MPEP 609. Draw line through